Darin Gwartney, DO
Sports Medicine · Pryor, OKNPI 1003107855
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $564, 3.4 times the $167 reported in 2019.
Across 104 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$272
- AbbVie$219
- Lilly USA, LLC$186
- Amgen$172
- AstraZeneca$149
- Novo Nordisk$132
- plus $655 from 16 others
What the payments were for
- Food & beverage$1,785100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 19 | $272 |
| AbbVie | 10 | $219 |
| Lilly USA, LLC | 11 | $186 |
| Amgen | 10 | $172 |
| AstraZeneca | 10 | $149 |
| Novo Nordisk | 8 | $132 |
| Boehringer Ingelheim | 6 | $100 |
| Lundbeck LLC | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 4 | $69 |
| Bayer | 4 | $58 |
| Pacira Therapeutics, Inc. | 2 | $50 |
| GSK | 3 | $49 |
| Astellas Pharma US Inc | 2 | $44 |
| Exact Sciences | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Bioventus LLC | 1 | $29 |
| Novartis | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Pacira Pharmaceuticals Incorporated | 1 | $18 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$1,785 in reported general payments places this provider in the 55th percentile of 55 sports medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 114 | $94,197 |
| EliquisApixaban | 99 | $85,705 |
| OzempicSemaglutide | 65 | $61,574 |
| MounjaroTirzepatide | 40 | $50,531 |
| TrulicityDulaglutide | 48 | $50,379 |
| FarxigaDapagliflozin Propanediol | 50 | $41,447 |
| GlyxambiEmpagliflozin/Linagliptin | 48 | $40,678 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 54 | $39,412 |
| RybelsusSemaglutide | 22 | $28,768 |
| ProliaDenosumab | 16 | $27,481 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $26,534 |
| XareltoRivaroxaban | 30 | $25,414 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $23,948 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $11,479 |
| JanuviaSitagliptin Phosphate | 15 | $8,289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $100 | $134,875162 claims |
| Lilly USA, LLCMounjaro, Trulicity | $186 | $100,91088 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $149 | $94,725151 claims |
| Novo NordiskOzempic, Rybelsus | $132 | $90,34287 claims |
| PfizerEliquis | $272 | $85,70599 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $22 | $28,87574 claims |
| AmgenProlia | $172 | $27,48116 claims |
| GSKTrelegy Ellipta | $49 | $26,53430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 55 sports medicine providers in Oklahoma.
Other sports medicine in Pryor
- Antoine JabbourTulsa$55K
- John GlomsetNorman$47K
- Chad HansonTulsa$40K
- Michael MaxtedOklahoma City$23K
- Jaya ShanmugamBartlesville$18K
- Jason GriffinTulsa$17K
- Gwendolyn EmersonTulsa$13K
- Andrew EbertTulsa$11K
- Kevin DukesTulsa$8K
- George GhataOklahoma City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.